Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
| Title | Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D |
| Journal | Leuk Lymphoma |
| Volume | 58 |
| Issue | 10 |
| Pagination | 2501-2504 |
| Date Published | 2017 Oct |
| ISSN | 1029-2403 |
| DOI | 10.1080/10428194.2017.1298755 |
| Alternate Journal | Leuk. Lymphoma |
| PubMed ID | 28306371 |
